12.2
给药方案：不完整的药代动力学参数
在药代动力学研究中，完整的药物的药代动力学参数或特征曲线往往难以获得。在缺乏动物或人体的全面药代动力学数据时，药代动力学专家需要基于科学推断作出一定假设，以确定合适的给药方案。常见的假设之一是将生物利用度（F）设定为1（100%）。这一假设适用于药物未能完全进入全身循环的情形，导致患者出现暴露不足，…
许多药物的完整药代动力学谱通常未知或无法获得。
因此，研究人员在缺乏药代动力学数据的情况下，需要根据药物的安全性、有效性和治疗窗做出一些假设，以计算给药方案。
一个常见的假设是将生物利用度系数 F 设为 1 或 100%。
这可以确保如果药物未被完全吸收，患者将处于用药不足而非用药过量的状态。
群体药代动力学利用患者的平均人群特征以及来自患者的有限血清药物浓度样本。
由于计算机数据库的普及以及用于观察性数据分析的统计工具的发展，群体药代动力学在治疗药物监测中的应用已日益增加。
View the full transcript and gain access to JoVE Core videos
Q1: Why do researchers set the bioavailability factor to 1 when complete pharmacokinetic data is unavailable?
Setting the bioavailability factor, F, to 1 or 100% ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated. This conservative assumption prioritizes patient safety by erring on the side of caution when complete pharmacokinetic profiles remain unknown or unavailable.
Q2: What factors guide the selection of assumptions for dosage regimen calculations?
Pharmacokineticists select assumptions based on three key factors: the drug's safety profile, its efficacy, and its therapeutic range. These criteria ensure that educated assumptions about bioavailability and other parameters lead to appropriate dosage regimens that balance therapeutic effectiveness with patient protection.
Q3: How does population pharmacokinetics help when individual drug data is incomplete?
Population pharmacokinetics uses average patient population characteristics combined with limited serum drug concentration samples from patients to estimate dosing parameters. This approach has increased in therapeutic drug monitoring due to computerized databases and advanced statistical tools for analyzing observational data.
Q4: What role do computerized databases play in modern dosage regimen development?
Computerized databases enable population pharmacokinetics by storing and organizing large amounts of patient data and serum drug concentration information. Combined with statistical tools for observational data analysis, these databases facilitate the calculation of appropriate dosage regimens without requiring complete individual pharmacokinetic profiles.
Q5: Why is population pharmacokinetics increasingly used in therapeutic drug monitoring?
Population pharmacokinetics has gained prominence in therapeutic drug monitoring because it provides a practical alternative when complete pharmacokinetic profiles are unavailable. The availability of computerized databases and development of statistical tools for observational data analysis make this approach feasible and reliable for clinical practice.
Q6: What happens if a drug's bioavailability assumption is set too high?
If the bioavailability factor is set too high, patients may receive insufficient drug doses, resulting in undermedication and reduced therapeutic effectiveness. This is why researchers conservatively set F to 1 or 100% when complete absorption data is unknown, prioritizing patient safety over potential overmedication risks.
Q7: How do statistical tools support dosage regimen calculations in population pharmacokinetics?
Statistical tools designed for observational data analysis enable pharmacokineticists to extract meaningful pharmacokinetic information from limited serum drug concentration samples across patient populations. These tools help calculate reliable dosage regimens by identifying patterns and relationships in population-level data when individual complete profiles are unavailable.